Drug intelligence / Profile preview

Mimrit

Development stage: Unknown
Lead developer: Daiichi Sankyo
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

**Mimrit** is a freeze-dried, live-attenuated measles-mumps-rubella vaccine developed for prevention of measles, mumps, and rubella. The vaccine combines attenuated measles virus AIK-C strain, mumps virus RIT4385 strain, and rubella virus Takahashi strain. Vaccination induces pathogen-specific humoral and cellular immune responses that suppress viral replication following exposure. Daiichi Sankyo received Japanese manufacturing and marketing approval for Mimrit for Subcutaneous Injection on May 11, 2026. ([mhlw.go.jp](https://www.mhlw.go.jp/content/10900000/001266003.pdf))

Brand names: Mimrit

Targets

PVRL4 (Nectin cell adhesion molecule 4)PRR (Pattern recognition receptors)Sialoglycan (Cell-surface sialoglycan)SLAMF1 (SLAM family member 1)

Beyond the preview

Go deeper on Mimrit.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mimrit.

Explore the full profile